Microiontophoretic application of serotonin (5HT)(1B/1D) agonists inhibits trigeminal cell firing in the cat

Brain

Volumn 120, Issue 12, 1997, Pages 2171-2177

  Storer, R J ^a   Goadsby, Peter J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cluster headache; Headache; Migraine; Sumatriptan; Zolmitriptan

Indexed keywords

ERGOMETRINE; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CLUSTER HEADACHE; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; MICROIONTOPHORESIS; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE;

AFFERENT PATHWAYS; ANIMALS; CATS; ELECTRIC STIMULATION; HOMOCYSTEINE; HUMANS; IONTOPHORESIS; NEURONS; OXAZOLES; OXAZOLIDINONES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SPINAL CORD; SUMATRIPTAN; TRIGEMINAL NERVE; TRYPTAMINES;

EID: 0031441447     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.12.2171     Document Type: Article

References (63)

1. Bloom FE. To spritz or not to spritz: the doubtful value of aimless iontophoresis. [Review]. Life Sci 1974; 14: 1819-34.
2. Brandli P, Loffler B-M, Breu V, Osterwalder R, Maire J-P, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996; 64: 315-22.
3. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan inhibits central trigeminal nociceptive responses in an electrophysiological assay in the anaesthetized rat. In: Olesen J, Edvinsson L, editors. Messenger molecules in headache pathogenesis: monoamines, neuropeptides, purines and nitric oxide. Copenhagen: Proceedings of the 7th International Headache Research Seminar, 1996: 18.
4. Davis KD, Dostrovsky JO. Activation of trigeminal brain-stem nociceptive neurons by dural artery stimulation. Pain 1986; 25: 395-401.
5. Davis KD, Dostrovsky JO. Cerebrovascular application of bradykinin excites central sensory neurons. Brain Res 1988; 446: 401-6.
6. Diener HC. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In: Olesen J, Tfelt-Hansen P, editors. Proceedings of the International VIth Headache Seminar. Copenhagen, 1996:
7. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119-23.
8. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960; 10: 555-63.
9. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally [see comments]. Cephalalgia 1995; 15: 384-90. Comment in: Cephalalgia 1995; 15: 333-4.
10. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally [see comments]. Cephalalgia 1995; 15: 384-90. Comment in: Cephalalgia 1995; 15: 333-4.
11. Goadsby PJ. Bench to bedside: what have we learnt recently about headache? Curr Opin Neurol 1997; 10: 215-20.
12. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
13. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994a; 117: 427-34.
14. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994b; 34: 394-9.
15. 3H]-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29: 91-4.
16. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996; 67: 355-9.
17. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997; 190: 367-75.
18. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17: 153-8.
19. Goadsby PJ, Silberstein SD. Headache. Boston: Butterworth-Heinemann, 1997.
20. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114: 1001-11.
21. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7.
22. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, et al. Oral sumatriptan in acute migraine. Lancet 1991a; 338: 782-3.
23. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991b; 31: 365-71.
24. Goldstein DJ, Wang O. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study [abstract]. Cephalalgia 1997; 17: 245-6.
25. Goldstein J, Dahlof CGH, Diener H-C, Olesen J, Schellens R, Senard JM, et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 1996; 16: 497-502.
26. Gupta P, Brown D, Butler P, Ellis P, Grayson KL, Land GC, et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116: 2385-90.
27. 1b binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 1987; 243: 989-1001.
28. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. [Review]. Trends Pharmacol Sci 1996; 17: 103-5.
29. Hoskin KL, Goadsby PJ. CP122,288 has no effect on c-fos expression in the trigeminal nucleus caudalis after superior sagittal sinus stimulation [abstract]. Cephalalgia 1997; 17: 402-3.
30. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiological study. Brain 1996; 119: 249-56.
31. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996a; 119: 1419-28.
32. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). [Review]. Pharmacol Rev 1994; 46: 157-203.
33. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. [Review]. Cephalalgia 1994; 14: 401-10.
34. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. [Review]. Eur Neurol 1991; 31: 282-90.
35. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993a; 109: 788-92.
36. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993b; 629: 95-102.
37. Keller JT, Saunders MC, Beduk A, Jollis JG. Innervation of the posterior fossa dura of the cat. Brain Res Bull 1985; 14: 97-102.
38. Lambert GA, Goadsby PJ, Zagami AS, Duckworth JW. Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. Brain Res 1988; 453: 143-9.
39. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 1992; 597: 321-30.
40. Lee WS, Moussaoui SM, Moskowitz MA. Blockade by oral or parenteral RPR100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol. 1994; 112: 920-4.
41. 3H]alniditan. Mol Pharmacol 1996; 50: 1567-80.
42. 1D receptor agonist 311C90. In: Rose FC, editor. New advances in headache research, Vol. 4. London: Smith-Gordon, 1994: 3-4.
43. Martins IP, Baeta E, Paiva T, Campos J, Gomes L. Headaches during intracranial endovascular procedures: a possible model of vascular headache. Headache 1993; 33: 227-33.
44. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67: 375-8.
45. McNaughton FL. The innervation of the intracranial blood vessels and the dural sinuses. In: Cobb S, Frantz AM, Penfield W, Riley HA, editors. The circulation of the brain and spinal cord. New York: Hafner Publishing, 1966: 178-200.
46. 3H]sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995; 280: 175-8.
47. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. [Review]. Annu Rev Med 1993; 44: 145-54.
48. Nichols FT, Mawad M, Mohr JP, Hilal S, Adams RJ. Focal headache during balloon inflation in the vertebral and basilar arteries. Headache 1993; 33: 87-9.
49. O'Shaughnessy CT, Connor HE, Feniuk W. Extracellular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia 1993; 13: 175-9.
50. 3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors. Eur J Pharmacol 1996; 295: 271-4.
51. Phebus LA, Johnson KW, Audia JE, Cohen ML, Dressman BA, Fritz JE, et al. Characterization of LY334370, a potent and selective 5HT1F receptor agonist, in the neurogenic dural inflammation model of migraine pain [abstract]. Neurosci Abstr 1996; 22: 1331.
52. Rance D, Clear N, Dallman L, Llewellyn E, Nuttall J, Verrier H. Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor of oral absorption potential [abstract]. Headache 1997; 37: 328.
53. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813-56.
54. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995; 34: 255-61.
55. Siegel S. Nonparametric statistics for the behavioral sciences. London: McGraw-Hill, 1956.
56. Subcutaneous Sumatripan International Study Group. Treatment of migraine attacks with sumatriptan [see comments]. N Engl J Med 1991; 325: 316-21. Comment in: N Engl J Med 1991; 325: 353-4.
57. Subcutaneous Sumatripan International Study Group. Treatment of migraine attacks with sumatriptan [see comments]. N Engl J Med 1991; 325: 316-21. Comment in: N Engl J Med 1991; 325: 353-4.
58. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46: 522-6.
59. 3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedeberg's Arch Pharmacol 1995; 352: 263-75.
60. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine [see comments]. Arch Neurol 1996; 53: 180-4. Comment in: Arch Neurol 1996; 53: 1215-6.
61. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine [see comments]. Arch Neurol 1996; 53: 180-4. Comment in: Arch Neurol 1996; 53: 1215-6.
62. Wolff HG. Headache and other head pain. 2nd ed. New York: Oxford University Press, 1963.
63. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69-75.